Health‐related quality of life and disease‐specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population‐based study using the PROFILES registry
Authors:
- 4 July 2012
- journal article
- research article
- Published by Wiley in European Journal of Haematology
- Vol. 89 (4) , 311-319
Abstract
Background: This prospective population‐based study describes health‐related quality of life (HRQOL) and disease‐specific complaints of patients with multiple myeloma (MM) up to 10 yr post‐diagnosis.Methods: The Eindhoven Cancer Registry was used to select all patients diagnosed with MM from 1999 to 2010. Patients with MM completed the EORTC QLQ‐C30 and EORTC QLQ‐MY20 questionnaires at baseline (n = 156; 74% response rate) and 1 yr later (n = 80). The EORTC QLQ‐C30 was also completed by an age‐ and sex‐matched normative population (n = 500).Results: Patients with MM reported statistically significant and clinically relevant worse scores on all EORTC QLQ‐C30 scales (all P's at least < 0.01) compared to the norm. Also, patients with MM reported a mean decrease (e.g., worsening) between baseline and 1‐yr follow‐up scores for: quality of life (mean, 68 vs. 55, respectively, P < 0.001; 74% of patients had a deteriorated score), fatigue (33 vs. 39, P < 0.05; 50%), nausea and vomiting (6.3 vs. 13, P < 0.05; 71%), pain (33 vs. 43, P < 0.05; 59%), and dyspnea (17 vs. 33, P < 0.001; 66%). The most bothering symptoms during the past week were tingling hands/feet (32%), back pain (28%), bone aches/pain (26%), pain in arm/shoulder (19%), and feeling drowsy (18%). Also, 37% worried about their future health, 34% thought about their disease, and 21% worried about dying.Conclusion: Patients with MM experience a very high symptom burden and low HRQOL. Future studies should focus on possible mechanisms that can predict low HRQOL and high symptom burden in patients with MM and should investigate optimal ways to alleviate these.Keywords
This publication has 27 references indexed in Scilit:
- Guidelines for supportive care in multiple myeloma 2011British Journal of Haematology, 2011
- Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studiesLeukemia & Lymphoma, 2010
- Improved survival among younger but not among older patients with Multiple Myeloma in the Netherlands, a population-based study since 1989European Journal of Cancer, 2010
- The Relationships Among Physiologic Variables, Quality of Life, and Fatigue in Patients With Multiple MyelomaOncology Nursing Forum, 2009
- Bortezomib is associated with better health‐related quality of life than high‐dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX studyBritish Journal of Haematology, 2008
- Recent major improvement in long-term survival of younger patients with multiple myelomaBlood, 2008
- An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myelomaEuropean Journal of Cancer, 2007
- Treatment of Bendamustine and Prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisone—a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)Journal of Cancer Research and Clinical Oncology, 2006
- Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differencesEuropean Journal of Haematology, 2004
- The self‐administered comorbidity questionnaire: A new method to assess comorbidity for clinical and health services researchArthritis Care & Research, 2003